These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6372774)

  • 21. Comparative double-blind trial of the effectiveness and antigenicity of semisynthetic human insulin and purified porcine insulin in newly treated diabetic subjects.
    Larkins RG; Zajac J; Saunders R; Read A; Hopper JL
    Aust N Z J Med; 1986 Apr; 16(2):206-10. PubMed ID: 3530226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological and metabolic responses of patients with history of antibody-induced beef insulin resistance to treatment with beef, pork, human, and sulfated beef insulin.
    Davidson JK; Fineberg SE; De Meyts P; Fineberg NS; Galloway JA
    Diabetes Care; 1992 May; 15(5):702-4. PubMed ID: 1516491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects.
    Fireman P; Fineberg SE; Galloway JA
    Diabetes Care; 1982; 5 Suppl 2():119-25. PubMed ID: 6765521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of species of origin, purification levels, and formulation on insulin immunogenicity.
    Fineberg SE; Galloway JA; Fineberg NS; Goldman J
    Diabetes; 1983 Jul; 32(7):592-9. PubMed ID: 6345238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosynthetic human insulin improves postprandial glucose excursions in type I diabetics.
    Gulan M; Gottesman IS; Zinman B
    Ann Intern Med; 1987 Oct; 107(4):506-9. PubMed ID: 3307584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor binding studies and clinical effects of human insulin (recombinant DNA): studies in patients with newly diagnosed type i diabetes, type II diabetes, insulin resistance (type A and type B), insulin antibodies, insulin allergy, and "brittle" diabetes.
    Schlüter KJ; Kerp L
    Diabetes Care; 1982; 5 Suppl 2():152-60. PubMed ID: 6765528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetic control in patients treated with once or twice-daily insulin injections, including a comparison of conventional beef and highly purified pork insulins.
    Gray RS; Borsey DQ; Fraser DM; Kurtz AB; Rainbow S; Smith AF; Duncan LJ; Clarke BF
    Diabetologia; 1981 Sep; 21(3):206-10. PubMed ID: 7028552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human insulin and insulin pumps.
    Shuman CR
    Clin Ther; 1984; 6(4):380-7. PubMed ID: 6380721
    [No Abstract]   [Full Text] [Related]  

  • 29. A prospective study of the immunogenicity of porcine insulin in HLA-typed new insulin-treated diabetics.
    Almér LO; Ekberg G; Fankhauser S; Home PD; Worth R; Sailer S; Kurtz AB; Christy M
    Diabetes Res; 1985 Sep; 2(5):221-4. PubMed ID: 3905185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Free covalent aggregates of therapeutic insulin in blood of insulin-dependent diabetics.
    Robbins DC; Mead PM
    Diabetes; 1987 Feb; 36(2):147-51. PubMed ID: 3542642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extreme insulin resistance: a consequence of insulin switching?
    Keenan WF; Abgott MA
    J Fam Pract; 1988 Dec; 27(6):635-6. PubMed ID: 3058859
    [No Abstract]   [Full Text] [Related]  

  • 32. In defence of animal insulins.
    Singh J
    J Indian Med Assoc; 2002 Mar; 100(3):171-2. PubMed ID: 12408277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind crossover trial comparing human insulin (recombinant DNA) with animal insulins in the treatment of previously insulin-treated diabetic patients.
    Clark AJ; Wiles PG; Leiper JM; Knight G; Adeniyl-Jones RO; Watkins PJ; Ward JD; MacCuish AC; Keen H; Jones RH
    Diabetes Care; 1982; 5 Suppl 2():129-34. PubMed ID: 6765523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
    Schernthaner G; Borkenstein M; Fink M; Mayr WR; Menzel J; Schober E
    Diabetes Care; 1983; 6 Suppl 1():43-8. PubMed ID: 6343038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and allergenic potential of animal and human insulins.
    Schernthaner G
    Diabetes Care; 1993 Dec; 16 Suppl 3():155-65. PubMed ID: 8299472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antibodies against therapeutic animal insulins and homologous proteins in the course of diabetes in children and adolescents].
    Karczewska K
    Med Dosw Mikrobiol; 1974; 26(4):317-24. PubMed ID: 4475335
    [No Abstract]   [Full Text] [Related]  

  • 37. Reduction in insulin antibodies 42 months after transfer from porcine to human monocomponent insulins.
    Virgili F; Frigato F; Magnanini PG; Coronel GA; Iavicoli M
    Diabetes Res; 1988 Sep; 9(1):19-20. PubMed ID: 3071441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin.
    Kurtz AB; Matthews JA; Mustaffa BE; Daggett PR; Nabarro JD
    Diabetologia; 1980; 18(2):147-50. PubMed ID: 6988274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human cellular immune response to insulin: a study in unexposed control subjects and type I diabetic patients on acute and chronic treatment.
    Richens ER; Seward ME; Luqman WA; Hartog M
    Acta Diabetol Lat; 1986; 23(4):309-22. PubMed ID: 3551427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immunogenicity of new insulins.
    Deckert T
    Diabetes; 1985 Jun; 34 Suppl 2():94-6. PubMed ID: 3888748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.